Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
Abstract
The aim of the present study was to assess the outcome of acute ischemic stroke patients treated with tenecteplase. Patients with ischemic stroke who presented to the Basweshwar Teaching and General Hospital and Vatsalya Life Hospital Kalaburagi within a 3‐hour window and were treated with tenecteplase were included in a prospective observational trial. The patients had to be 18 years old or older. The study comprised forty patients. All participants provided written informed permission and the research was approved by the institution's ethical committee. In the trial, 40 patients received tenecteplase IV stroke thrombolysis. The research had a mean age of 61.36±12.48 years, with 70% of participants being male. Hypertension predominated at 60%, followed by dyslipidemia at 50%. Most patients had major artery stroke subtype, with all 20 infarct regions in the middle cerebral artery. The mean time from symptom onset to medical emergency was (116±11.49) minutes, while the mean “door to needle” duration was (55±17.23) minutes. At baseline, the study individuals had a mean NIHSS score of (11±3.16) and a median mRS score of 5 (range: 3‐5). Primary clinical efficacy outcome: NIHSS score improvement of 4 or more points at 24 h. The mean NIHSS scores at 2 and 24 hours were (10.48±5.16) and (9.34±5.23), respectively. We utilized “one‐way repeated measures analysis of variance” to find a significant difference in baseline and 24‐h NIHSS scores (p = 0.017). Tenecteplase is the safest, faster, and cheaper thrombolytic drug for acute ischemic stroke, and it works in rural and urban settings. More investigations on this innovative thrombolytic drug will show its superiority even in rural settings, reducing stroke epidemics, especially in this endovascular care era.
How to cite this article:
Avinash Alashetty and S. Sumangala. A Prospective Observational Assessment of the Results of Tenecteplase Treatment for Patients With Acute Ischemic Stroke.
DOI: https://doi.org/10.36478/10.59218/makrjms.2024.4.414.417
URL: https://www.makhillpublications.co/view-article/1815-9346/10.59218/makrjms.2024.4.414.417